Released Aug 12, 2025, before the open
10-Q filed Aug 12, 2025, 43 days after period end · 0002023658-25-000098
Q2 2025 · 10-Q
Revenue—
Net Income-$27.39M-$27.39M N/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.50-$0.50 N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$32,018,000N/M
Operating Cash Flowderived-$25,594,000N/M
Free Cash Flowderived-$25,594,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|
| Net Income | -$27.39M | -$17.05M | -$9.29M |
| EPS Diluted | -$0.50 | -$19.01 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bicara Therapeutics Inc. · CIK 2023658 · Engraved from SEC EDGAR